-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明，無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
MiNK Therapeutics (NASDAQ:INKT) Shares Down 0.4%
MiNK Therapeutics (NASDAQ:INKT) Shares Down 0.4%
MiNK Therapeutics, Inc. (NASDAQ:INKT – Get Rating)'s stock price dropped 0.4% during trading on Wednesday . The stock traded as low as $2.50 and last traded at $2.51. Approximately 7,858 shares traded hands during mid-day trading, a decline of 95% from the average daily volume of 169,116 shares. The stock had previously closed at $2.52.
Analysts Set New Price Targets
Separately, HC Wainwright initiated coverage on shares of MiNK Therapeutics in a research note on Wednesday, August 10th. They issued a "buy" rating and a $7.00 price target for the company.
Get MiNK Therapeutics alerts:MiNK Therapeutics Price Performance
The business's 50 day moving average is $2.34 and its 200 day moving average is $2.02. The stock has a market cap of $84.80 million, a price-to-earnings ratio of -3.22 and a beta of -0.63.
MiNK Therapeutics (NASDAQ:INKT – Get Rating) last issued its earnings results on Thursday, November 3rd. The company reported ($0.19) EPS for the quarter, topping analysts' consensus estimates of ($0.23) by $0.04. As a group, analysts forecast that MiNK Therapeutics, Inc. will post -0.84 earnings per share for the current year.Hedge Funds Weigh In On MiNK Therapeutics
A hedge fund recently bought a new stake in MiNK Therapeutics stock. First Republic Investment Management Inc. bought a new position in shares of MiNK Therapeutics, Inc. (NASDAQ:INKT – Get Rating) in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 81,500 shares of the company's stock, valued at approximately $172,000. First Republic Investment Management Inc. owned approximately 0.24% of MiNK Therapeutics at the end of the most recent quarter. 1.07% of the stock is currently owned by institutional investors.
About MiNK Therapeutics
(Get Rating)
MiNK Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases, which is in Phase 1 clinical trials.
Read More
- Get a free copy of the StockNews.com research report on MiNK Therapeutics (INKT)
- The Question of a Fed Pivot Isn't If, It's When, Here's Why
- Top 10 Searched Stocks on MarketBeat All-Access
- 3 Dividend Kings With Royally Good Upside
- Institutions Sell The Rallies In Toll Brothers Stock
- Low Beta, High Yield Campbell Soup Company Is Mmm Mmm Good
Receive News & Ratings for MiNK Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MiNK Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
MiNK Therapeutics, Inc. (NASDAQ:INKT – Get Rating)'s stock price dropped 0.4% during trading on Wednesday . The stock traded as low as $2.50 and last traded at $2.51. Approximately 7,858 shares traded hands during mid-day trading, a decline of 95% from the average daily volume of 169,116 shares. The stock had previously closed at $2.52.
明克治療公司(納斯達克代碼：iNKT-GET Rating)週三股價下跌0.4%，盤中一度跌至2.50美元，最新報2.51美元。午盤，約有7,858股股票易手，較169,116股的日均成交量下降95%。此前該股收盤價為2.52美元。
Analysts Set New Price Targets
分析師設定新的價格目標
Separately, HC Wainwright initiated coverage on shares of MiNK Therapeutics in a research note on Wednesday, August 10th. They issued a "buy" rating and a $7.00 price target for the company.
另外，HC Wainwright在8月10日星期三的一份研究報告中啟動了對水貂治療公司股票的報道。他們對該公司的評級為“買入”，目標價為7美元。
MiNK Therapeutics Price Performance
水貂治療公司的價格表現
The business's 50 day moving average is $2.34 and its 200 day moving average is $2.02. The stock has a market cap of $84.80 million, a price-to-earnings ratio of -3.22 and a beta of -0.63.
該業務的50日移動均線切入位在2.34美元，200日移動均線切入位在2.02美元。該股市值為8480萬美元，本益比為-3.22倍，貝塔係數為-0.63倍。
Hedge Funds Weigh In On MiNK Therapeutics
對沖基金入股水貂治療公司
A hedge fund recently bought a new stake in MiNK Therapeutics stock. First Republic Investment Management Inc. bought a new position in shares of MiNK Therapeutics, Inc. (NASDAQ:INKT – Get Rating) in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 81,500 shares of the company's stock, valued at approximately $172,000. First Republic Investment Management Inc. owned approximately 0.24% of MiNK Therapeutics at the end of the most recent quarter. 1.07% of the stock is currently owned by institutional investors.
一家對沖基金最近買入了水貂治療公司的新股。根據第一共和投資管理公司在第三季度購買了水貂治療公司(納斯達克：iNKT-GET評級)股票的新頭寸，該公司在最近提交給美國證券交易委員會(美國證券交易委員會)的檔案中稱。該基金購買了81,500股該公司股票，價值約172,000美元。截至最近一個季度末，First Republic投資管理公司擁有水貂治療公司約0.24%的股份。該股目前由機構投資者持有1.07%的股份。
About MiNK Therapeutics
關於水貂治療公司
(Get Rating)
(獲取評級)
MiNK Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases, which is in Phase 1 clinical trials.
明克治療公司是一家臨床階段的生物製藥公司，致力於同種異體、現成、不變的自然殺傷T(INKT)細胞療法的發現、開發和商業化，以治療癌症和其他免疫介導性疾病。它的候選產品是AGENT-797，這是一種現成的同種異體藥物，用於iNKT細胞治療和治療各種骨髓瘤疾病，目前處於第一階段臨床試驗。
Read More
閱讀更多內容
- Get a free copy of the StockNews.com research report on MiNK Therapeutics (INKT)
- The Question of a Fed Pivot Isn't If, It's When, Here's Why
- Top 10 Searched Stocks on MarketBeat All-Access
- 3 Dividend Kings With Royally Good Upside
- Institutions Sell The Rallies In Toll Brothers Stock
- Low Beta, High Yield Campbell Soup Company Is Mmm Mmm Good
- 免費獲取StockNews.com關於水貂治療的研究報告(INKT)
- 美聯儲軸心的問題不是是否，而是何時，這是為什麼
- 在MarketBeat All-Access上搜索的前10名股票
- 王室利多的3個股息之王
- 機構拋售Toll Brothers股票的漲勢
- 低貝塔，高產量的坎貝爾湯公司很好
Receive News & Ratings for MiNK Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MiNK Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
接受水貂治療日報的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收對水貂治療和相關公司的最新新聞和分析師評級的每日簡要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國，moomoo上的投資產品和服務由Moomoo Financial Inc.提供，一家受美國證券交易委員會（SEC）監管的持牌主體。 Moomoo Financial Inc.是金融業監管局（FINRA）和證券投資者保護公司（SIPC）的成員。
在新加坡，moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供，該公司受新加坡金融管理局（MAS）監管(牌照號碼︰CMS101000) ，持有資本市場服務牌照 (CMS) ，持有財務顧問豁免（Exempt Financial Adviser）資質。本內容未經新加坡金融管理局的審查。
在澳大利亞，moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供，該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構（AFSL No. 224663）。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件，這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大，透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供，並受加拿大投資監管機構（CIRO）監管。
在馬來西亞，moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供，該公司受馬來西亞證券監督委員會（SC）監管(牌照號碼︰eCMSL/A0397/2024) ，持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.，Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國，moomoo上的投資產品和服務由Moomoo Financial Inc.提供，一家受美國證券交易委員會（SEC）監管的持牌主體。 Moomoo Financial Inc.是金融業監管局（FINRA）和證券投資者保護公司（SIPC）的成員。
在新加坡，moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供，該公司受新加坡金融管理局（MAS）監管(牌照號碼︰CMS101000) ，持有資本市場服務牌照 (CMS) ，持有財務顧問豁免（Exempt Financial Adviser）資質。本內容未經新加坡金融管理局的審查。
在澳大利亞，moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供，該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構（AFSL No. 224663）。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件，這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大，透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供，並受加拿大投資監管機構（CIRO）監管。
在馬來西亞，moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供，該公司受馬來西亞證券監督委員會（SC）監管(牌照號碼︰eCMSL/A0397/2024) ，持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.，Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能，分享給你的好友吧